Patent intelligence · US
US 9018244
Benzopyran compounds, compositions and uses thereof
Benzopyran compounds, compositions and uses thereof
Patent details — US 9018244
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 28, 2015
- Expiration
- Apr 23, 2035
- Applicant
- Olema Pharmaceuticals, Inc.
- Claims
- 50
- CPC classes
- A61K, A61K31/4025, A61K31/565, A61K31/675
Quick answer
US 9018244 (Benzopyran compounds, compositions and uses thereof) is held by Olema Pharmaceuticals, Inc.. Status: granted. Granted Apr 28, 2015. Expires Apr 23, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Olema Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 50
- CPC classes
- A61K, A61K31/4025, A61K31/565, A61K31/675, A61K45/06, A61P
More from Olema Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428379
Acylsulfonamide KAT6A inhibitors
granted -
US 12370181
Regimens of estrogen receptor antagonists
granted -
US 11672785
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
granted -
US 11229630
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
granted -
US 10624878
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
granted -
US 10292971
Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs
granted -
US 8071545
Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism
granted
Related coverage
Frequently asked questions
What is US patent 9018244?
US 9018244 (Benzopyran compounds, compositions and uses thereof) is held by Olema Pharmaceuticals, Inc.. Status: granted. Granted Apr 28, 2015. Expires Apr 23, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9018244?
Olema Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 9018244 expire?
Our index shows an expiration date of Apr 23, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.